Biomarkers for Sepsis in Childre
- Conditions
- sepsisInfection - Other infectious diseases
- Registration Number
- ACTRN12624000782538
- Lead Sponsor
- Murdoch Children's Research Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 240
•Aged <18 years; AND
•Admission to hospital; AND
•Treatment with intravenous (IV)/ intramuscular (IM)/ intraosseous (IO) antibiotics pre-hospital or in ED; AND
•Circulatory support (fluid bolus or inotropic support) pre-hospital or in ED
OR
Admission diagnosis of suspected sepsis, septicaemia or septic shock
Fluid bolus defined as equal to or greater than 5ml/kg or 500mls administered over less than or equal to 30 minutes to treat impaired perfusion (not dehydration)
Inotropic support defined as intravenous infusion of inotrope/vasopressor
a)Patients not initially seen in the Emergency Department (i.e. transferred to the ward including ICU)
b)Patients presenting with trauma who receive antibiotics for prophylaxis or circulatory support for blood loss
c)Patients transferred from another hospital if > 24 hours since presentation
d)Patients transferred from another hospital ward to ED
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ovel biomarker for early sepsis diagnosis[Novel biomarkers will be identified from discard blood samples taken during routine clinical care of children with suspected sepsis. Once the patients diagnosis is known, the samples will be analysed and compared with healthy controls to discover, validate, and verify suitability for commercialisation. Blood samples will be taken during routine initial investigations for children with suspected sepsis as per normal clinical care. Instead of the samples being discarded following laboratory analysis, they will be stored at -80 degrees celcius. Consent for biomarker analysis will be obtained, and once the patient diagnosis is known, the samples will be analysed for mRNA and protein signatures.]
- Secondary Outcome Measures
Name Time Method ovel biomarkers for risk stratification of children with sepsis[Novel biomarkers will be identified from discard blood samples taken during routine clinical care of children with suspected sepsis. Once the patients illness severity is known, the samples will be analysed and compared with healthy controls to discover, validate, and verify suitability for commercialisation. Blood samples will be taken during routine initial investigations for children with suspected sepsis as per normal clinical care. Instead of the samples being discarded following laboratory analysis, they will be stored at -80 degrees celcius. Consent for biomarker analysis will be obtained, and once the patients severity of illness is known, the samples will be analysed for mRNA and protein signatures.]